{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:59:08Z","timestamp":1790913548717,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":133,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101249","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:37:29Z","timestamp":1778823449000},"page":"101249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intracranial efficacy of combined immune checkpoint inhibitors and platinum plus etoposide therapy in patients with extensive-disease small-cell lung cancer and brain metastases"],"prefix":"10.1016","volume":"48","author":[{"given":"Kenta","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5869-8494","authenticated-orcid":false,"given":"Toshihiro","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigen","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kurishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Hizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101249_bib0001","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ctarc.2026.101249_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","article-title":"SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection","volume":"18","author":"Wang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0003","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"IMpower133 Study Group, first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101249_bib0004","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"CASPIAN investigators, Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (Caspian): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101249_bib0005","doi-asserted-by":"crossref","unstructured":"L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, et al., Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from Caspian, ESMO Open. 7 (2022) 100408. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100408.","DOI":"10.1016\/j.esmoop.2022.100408"},{"key":"10.1016\/j.ctarc.2026.101249_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer."},{"key":"10.1016\/j.ctarc.2026.101249_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2022.166557","article-title":"Small-cell lung cancer brain metastasis: from molecular mechanisms to diagnosis and treatment","volume":"1868","author":"Zhu","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Basis. Dis."},{"key":"10.1016\/j.ctarc.2026.101249_bib0008","first-page":"265","article-title":"Radiation therapy for brain metastases: an ASTRO clinical practice guideline, Pract","volume":"12","author":"Gondi","year":"2022","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0009","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrneurol.2016.185","article-title":"Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours","volume":"13","author":"Makale","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.893264","article-title":"The cognitive effects of radiotherapy for brain metastases","volume":"12","author":"Lehrer","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0011","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.critrevonc.2019.07.012","article-title":"Systemic therapy for brain metastases","volume":"142","author":"Rick","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0012","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3816\/CLC.2008.n.006","article-title":"Chemotherapy for brain metastases in small-cell lung cancer","volume":"9","author":"Chen","year":"2008","journal-title":"Clin. Lung Cancer."},{"key":"10.1016\/j.ctarc.2026.101249_bib0013","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1200\/JCO.2005.03.2946","article-title":"Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy","volume":"24","author":"Seute","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1002385","article-title":"Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer","volume":"12","author":"Rittberg","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0015","article-title":"J-TAIL-2: a prospective, observational study of atezolizumab combined with carboplatin and etoposide in patients with extensive-stage SCLC in Japan","volume":"6","author":"Miyauchi","year":"2025","journal-title":"JTo Clin. Res. Rep."},{"key":"10.1016\/j.ctarc.2026.101249_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105325","article-title":"Platinum Plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED)","volume":"10","author":"Shiraishi","year":"2025","journal-title":"ESMo Open."},{"key":"10.1016\/j.ctarc.2026.101249_bib0017","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27560","article-title":"Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors","volume":"3","author":"Eggermont","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctarc.2026.101249_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000648","article-title":"Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective","volume":"8","author":"Quinn","year":"2020","journal-title":"J. ImmunOther Cancer."},{"key":"10.1016\/j.ctarc.2026.101249_bib0019","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fonc.2018.00414","article-title":"Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease","volume":"8","author":"Kamath","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057388","article-title":"Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases","volume":"5","author":"Berghoff","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctarc.2026.101249_bib0021","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0022","article-title":"The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status","volume":"5","author":"Shao","year":"2022","journal-title":"Cancer Rep."},{"key":"10.1016\/j.ctarc.2026.101249_bib0023","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3390\/cancers17101603","article-title":"Outcomes in patients with non-small-cell lung cancer with brain metastases: a real-world data study from a resource-limited country","volume":"17","author":"Randjelovic","year":"2025","journal-title":"Cancers"},{"issue":"Suppl 5","key":"10.1016\/j.ctarc.2026.101249_bib0024","first-page":"v52","article-title":"Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies","volume":"3","author":"Myall","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.ctarc.2026.101249_bib0025","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s12672-024-01560-6","article-title":"Radiotherapy in patients with brain metastases with and without concomitant immunotherapy: comparison of patient outcome and neurotoxicity","volume":"15","author":"Elyan","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0026","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(22)00271-6","article-title":"Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis","volume":"23","author":"Gaebe","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0027","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101249_bib0028","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with Nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J. Thorac. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:49:42Z","timestamp":1790912982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"alternative-id":["S2468294226001607"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101249","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracranial efficacy of combined immune checkpoint inhibitors and platinum plus etoposide therapy in patients with extensive-disease small-cell lung cancer and brain metastases","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101249"}}